Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on November 10, 2014, by Xenon Pharmaceuticals Inc., a Canadian corporation. The report details a specific corporate event occurring on the same date, concurrent with the closing of the Company's initial public offering (IPO).
Key Financial Metrics
The filing reports a private placement transaction rather than standard operating financial results. Key figures include:
- Shares Issued: 495,000 common shares.
- Purchaser: Roche Finance Ltd.
- Aggregate Purchase Price: USD$4,455,000.
- Price Per Share: USD$9.00 (matching the IPO public offering price).
- Underwriter Fees: USD$311,850 paid from the aggregate purchase price for financial advisory services.
- Liquidity Impact: Proceeds were paid in immediately available funds.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt.
Material Changes
The primary material change is the issuance of 495,000 unregistered common shares to Roche Finance Ltd. pursuant to a Common Share Put Agreement dated March 19, 2014. This transaction was exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Outlook, Risks, and Unusual Items
The filing does not contain management commentary on future guidance, general risks, or contingencies beyond the specific transaction details. The transaction is noted as an investment by Roche, not for distribution, with appropriate legends affixed to the shares.
Investor Verification Checklist
- Verify the terms of the Common Share Put Agreement dated March 19, 2014, between Xenon and Roche.
- Confirm the total capital raised in the concurrent IPO to assess the proportion of this private placement.
- Review the impact of the USD$311,850 advisory fee on the net proceeds received by the Company.
- Check subsequent filings for any vesting schedules or lock-up periods associated with the shares issued to Roche.